Risultati di ricerca
1 mag 2024 · Classification. Renal cell carcinoma (RCC) is not a single entity, but rather a collection of different types of tumours, each derived from the various parts of the nephron (epithelium or renal tubules) and possessing distinct genetic characteristics, histological features, and, to some extent, clinical phenotypes.
17 apr 2024 · The Bosniak classification system of renal cystic masses, now known as Bosniak v2005, divides renal cystic masses into five categories based on imaging characteristics on contrast-enhanced CT, and helps predict a risk of malignancy and suggests either follow-up or treatment.
2 mag 2024 · Most common renal epithelial tumor, accounting for ~2% of all malignancies, typically with clear cytoplasm and a compact nested or acinar growth pattern, intersected by delicate vasculature and with characteristic alterations to chromosome 3p involving VHL (von Hippel-Lindau) gene inactivation.
17 apr 2024 · The initial classification of renal tumours was established in 1981 by the WHO, focusing exclusively on renal cell carcinoma (RCC). Over five decades, there has been a continuous process of altering classifications. The previous classifications of RCC were established based on different parameters.
3 mag 2024 · Li et al. perform comprehensive multi-omics characterization of a broad range of renal cell carcinomas, improving our understanding of the biology, proteogenomics, post-translational modifications, and metabolism of kidney cancer. These findings identify important biomarkers IGF2BP3, PYCR1, GPNMB, ADGRF5, MAPRE3, PIGR, and SOSTDC1 that illuminate molecular differences within renal cell carcinoma.
24 apr 2024 · We examined the transcriptional profiles of RCC tumors representing key molecular pathways, from a multi-institutional, real-world patient cohort, including ccRCC (n = 508) and centrally-reviewed nccRCC (n = 149) samples. ccRCC had increased angiogenesis signature scores compared to the heterogeneous group of nccRCC tumors (mean z ...
25 apr 2024 · Figure 1. Biomarker-based approaches for the treatment of patients with metastatic renal cell carcinoma. (A) Molecular clusters identified across the JAVELIN Renal 101 (JR101) and IMmotion151 datasets with responses to treatment. Correlations with clinical outcomes were not presented in cluster 7 in the JR101 trial.
